anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, veterinary science. SUBSTANCE: method deals with diagnostics or prophylaxis of yersiniosis and pseudotuberculosis. Serum is obtained due to immunization of rabbits, moreover, antigen should be introduced intravenously by the following scheme: 0.09-0.11 ml thrice at 2-3-d-long interval and in 7-8 d - two more injections at 2-3-d-long interval. As for adsorbents, one should apply microbial masses of reference strains 189 GISK and 207 GISK. The serum obtained enables to differentiate virulent strains of yersiniosis and pseudotuberculosis agents against nonvirulent yersinia and other enterobacteria more accurately. EFFECT: higher efficiency of differentiation. 2 tbl
Patients will be evaluated at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months after the start of the trial. This evaluation will include a clinical evaluation and a biological (IGF-I, IGFBP-3, leptin, ghrelin, adiponectin, mineral metabolism, thyroid function, 24 hours urinary cortisol, as well as conventional electrolyte tolerance parameters), psychological and nutritional study body composition by absorptiometry at 0, 12 and 24 months. Evaluations will be conducted at the Center for Clinical Investigation at Hospital Robert Debre. The primary endpoint will be the linear growth rate 1 year after the start of the trial expressed in cm/1 year in the group with hGH compared to the placebo group. The secondary endpoints will be the height velocity expressed in SDS (standard deviation score), the data of body composition and psychological changes that will be assessed between the 2 arms at the end of the two years of the clinical trial. The data of body composition obtained by dual photon absorptiometry and biological data of mineral metabolism and growth factors are expressed in Z score compared to normal references that we have established in France, in healthy subjects according to age, gender and pubertal stage.
Half of the participating hospitals will be in the intervention group for the first 6 months. The intervention will switch to the control group after the 6 months.
Law enforcement officers (LEOs) are exposed to significant stressors, elevating their risk for aggression and excessive use of force. Such dysfunctional stress reactivity can lead to devastating consequences for their community, including unjustified shootings, severe beatings, and fatal chokings. It can also lead to serious consequences for the LEOs, including elevated incidence of post-traumatic stress disorder, burnout, alcohol misuse, depression, and suicide. A recent meta-analysis of LEO stress reduction programs found little evidence to demonstrate that such approaches are effective, highlighting the urgent need for preventive interventions targeting the stress inherent to policing. Mindfulness training is a promising approach with high-stress populations that has been shown effective in reducing stress and increasing resilience. In a recent pilot feasibility study (R21AT008854), the study team established initial feasibility, acceptability, and adherence to procedures in a single-site RCT assessing Mindfulness-Based Resilience Training (MBRT), a preventive intervention designed to improve LEO mental health and resilience, and reduce aggression and excessive use of force. The R21 data suggest physiological mechanisms and potential clinical benefit in a sample of LEOs. Relative to waitlist control, MBRT participants showed improvements in stress reactivity, aggression, burnout, occupational stress, sleep disturbance, and psychological flexibility. Implemented at two sites, the proposed study is designed to establish optimal protocols and procedures for a future full-scale, multi-site trial assessing effects of MBRT versus an attention control (Stress Management Education) and a no-intervention control, on physiological, behavioral, and psychological outcomes. To prepare for this future clinical trial, this study will: a) enhance efficiency of recruitment, engagement and retention; b) optimize lab, assessment, and data management procedures; c) optimize intervention training and ensure fidelity to intervention protocols; and d) assess participant experience and optimize outcome measures across sites. The long-term objective of this line of research is to develop an intervention that will reduce violence and increase resilience among LEOs, as well as yield significant benefits for communities and residents they serve.
Vinorelbine 35 mg/m2 at day 1 as an i.v. infusion over 10 minutes or gemcitabine 1250 mg/m2 as a 30 minutes infusion at day 1. G-CSF will be started at day 4 at 10mcg/kg b.w. split in two daily doses, until the end of the stem cell collection procedure, with the first collection attempt on day 8.
PURPOSE:A preventive for infectious diseases comprising a specific mannoglucan derivative as an active ingredient. CONSTITUTION:A preventive for infectious diseases comprising a mannoglucan derivative having a fundamental repeating unit shown by the formula I (G is D-glucose residue; X and Y are group shown by the formula II, formula III, or alpha-D-mannose residue) as an active ingredient. It has effects on quantitative improvement in leukocyte, especially in neutrophils in animals and human, and it alone is fully expected to have effects on complicated infectious diseases. It effects are doubled by using a chemotherapeutic drug with it. The preventive is expected to have effects on various infectious disease caused by Escherichia coli and other bacteria (e.g., Pseudomonas aeruginosa, Streptococcus, Staphylococcus, Diplococcus pneumoniae, etc.) and fungi. Suppository, tablet, capsule, powder, etc. besides intravenous injection and intramuscular injection may be cited as the dosage form. A dose is sufficiently 0.1-100mg/kg/day.
PURPOSE:To easily and surely set the recording density of an image at a desired value by displaying the recording density designated by an input means, sending an identification signal with an image signal, and reproducing it. CONSTITUTION:Image information reading density from an accumulative type fluorescent material sheet 10 is displayed, and the signal representing the density is inputted to a signal processing part 22. In such a case, when a desired picture element is designated by operating a keyboard, a digital code EI representing the image density is outputted from a code input device 23. The processing part 22 performs the averaging of the image signal Sd, and generates a signal of one picture element, and outputs the signal EI as the identification signal simultaneously. At this time, erroneous setting for the setting of desired recording density can be eliminated because the state of the image desired to reproduce and record is known. Thereby, it is possible to easily and surely set the recording density at the desired value.
Induction therapy: mFOLFOX6 regimen + bevacizumab. lasting 2 cycles. Combination therapy: mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody. Every 2 weeks is a cycle.
Topiramate is a medication that is widely used for the treatment of adult and pediatric patients with seizures and has been shown in preliminary studies to be effective for migraine prevention in adults. This is an outpatient, randomized, double-blind, placebo-controlled study to confirm preliminary studies of the effectiveness of topiramate in the prevention of migraine attacks. The study is composed of 4 phases: pretreatment, double-blind treatment for 20 weeks, a blinded transition, and an open-label extension. During the pretreatment phase patients discontinue all medication for migraine prevention and keep a daily record of headache information in a diary. Patients with 3 to 8 migraines, but not more than 15 headache days, during the pretreatment phase continue in the double-blind treatment phase. In the 20-week double-blind treatment phase, oral topiramate tablets (or placebo) are taken daily beginning at 25 mg once daily for 1 week, increasing to twice daily doses of up to a maximum of 8 tablets (200 mg) per day during the 8-week titration period, and maintained at that dose during the 12-week maintenance period. Patients who successfully complete the double-blind therapy phase may continue in an open-label extension (32 weeks), during which the study medication (topiramate or placebo) will be decreased and simultaneously topiramate (open-label) will be administered at increasing doses. During the study, patients will maintain headache and medication records to document the following: occurrence and duration of headaches; severity of headache pain; associated symptoms, such as nausea, vomiting, photophobia (avoidance and dread of light), phonophobia (fear of sound); and medication taken to relieve headache pain or symptoms. The primary measure of effectiveness is the percent reduction in the frequency of monthly migraine episodes during the entire double-blind treatment phase compared with the pretreatment phase. Other assessments of effectiveness include the percent of patients responding to treatment (\>= 50% reduction in average monthly migraine attacks) during the double-blind treatment phase compared with the pretreatment phase, the reduction in number of migraine days/month during treatment, and the reduction in severity and duration of migraines during treatment. Safety assessments include the incidence of adverse events throughout the study, and measurement of vital signs (pulse, blood pressure, body weight), physical examinations, and clinical laboratory tests (hematology, biochemistry, and urinalysis) at specified intervals. The study hypothesis is that the decrease in the mean monthly migraine rate is greater in the topiramate group than in the placebo group.

Oral topiramate tablets 25 mg or placebo tablets, beginning at 25 mg once daily for 1 week, increasing to twice daily doses of up to a maximum of 8 tablets (200 mg) during the 8-week titration period, and maintained at that dose during the 12-week maintenance period (20 weeks total duration).
NEW MATERIAL:An aminocyclitol of formulaI(Y is halogen or acyloxy; OR<1> is hydroxyl group which may be protected). EXAMPLE:6,7,8-Triacetoxy-1-bromomethyl-3-oxo-2-oxa-4-azabicyclo[3.3.1] nonane. USE:Useful as medicines, food additives and feed additives for animals, having metabolic inhibitory action on carbohydrates, e.g. hyperglycemic inhibitory action, in men and animals, and useful for preventing diseases caused by hyperglycemic symptoms and hyperglycemia, e.g. obesity, hyperadiposis, hyperlipemia, diabetes and prediabetes, and diseases caused by the sugar metabolism by microorganisms in the oral cavity, e.g. dental caries. PROCESS:A compound of formula II (R<2> is alkyl, aryl or aralkyl) is reacted with a halogenating agent in a solvent, preferably water or methyl alcohol, to give the compound of formulaI.
PROBLEM TO BE SOLVED: To obtain an aerosol type hair foam having slight stickiness, an excellent settling property and its excellent durability. SOLUTION: In this aerosol type hair foam using a stock solution and a propellant, a >=16C higher alcohol is contained in the stock solution. Cetanol or stearyl alcohol is preferable as the >=16C higher alcohol. The content of the higher alcohol in the stock solution is preferably 0.01-10.0 wt.%. 2-Ethylhexyl isononanoate and a mink oil are preferably contained in the stock solution. The contents of 2-ethylhexyl isononanoate and the mink oil are preferably 0.1-20 wt.%, respectively.
The study will be a virtual 10-week multi-site, assessor-blinded, randomized controlled trial with an embedded qualitative component. The study will be conducted in real time using secure videoconferencing software (Zoom). Participants will be randomized 1:1 to a 10-week Seated Exercise group or a delayed 2-week Seated Exercise Group (Boot Camp). Seated exercise sessions will be delivered and supervised by a trained instructor.

Participants will use their own computer, laptop, or tablet for the zoom sessions. No Zoom sessions will be recorded. Caregivers will be invited to attend each exercise session to provide support and assistance but are not obliged to attend. A caregiver, friend, or family member will be required for each assessment to participate in the study.
In the study, the MIND-BE program will be applied to the nurses (n=49) in the intervention group. Considering the studies on mindfulness on nurses, it is planned to practice mindfulness for 60 minutes once a week for 8 weeks. Mindfulness practice will be done online using appropriate platforms on the days and hours determined by Hilal Altundal (H.A.), who has a Mindfulness Institute-approved document. In the control group (n=49), no intervention will be made for 8 weeks. Results will be collected through data collection forms before the MIND-BE program, after the MIND-BE program is completed (8th week), and one month after the MIND-BE program is completed (12th week). The data collection forms applied to all nurses in the intervention and control groups at the beginning of the study will be applied again at the end of the 8th and 12th weeks. The primary expected outcome of the study is the effect of the MIND-BE program on nurses' resilience, posttraumatic growth, mindfulness, and self-compassion. The secondary expected result of the study is to determine the effect of the MIND-BE program on the mental health of nurses.
This group will consist of women who desire uterine preservation. Women will be randomized 1:1 to GFA or Myomectomy (laparoscopic or abdominal).
Grounding refers to having direct contact with the Earth, such as walking barefoot or lying on the ground. Research has found that grounding can improve inflammation, free radical damage, blood pressure, sleep quality, pain, stress, mood, and wound healing. However, there has been no re-search on the effect of utilizing grounding for patients with Alzheimer's disease (AD). Thus, in this study, the investigators explore the effectiveness of grounding as a non-pharmacological therapy for treating sleep disturbances, anxiety, and depression in patients with mild AD.

Patients with mild AD were enrolled in the study. The electrochemical analyzer CHI 1205b was employed to check the electrochemical signals at acupoints KI1 and GV16. The investigators used the Pittsburgh Sleep Quality Index (PSQI), Beck Anxiety Inventory (BAI), and Beck Depression Inventory-II (BDI-II) to evaluate sleep quality, anxiety, and depression, respectively, at weeks 0 and 12.
BACKGROUND: Vaccine Adverse Events ReportingSystem (VAERS) is a promising resource of tracking adverse events following immunization. Medical Dictionary for Regulatory Activities (MedDRA) terminology used for coding adverse events in VAERS reports has several limitations. We focus on developing an automated system for semantic extraction of adverse events following vaccination and their temporal relationships for a better understanding of VAERS data and its integration into other applications. The aim of the present studyis to summarize the lessons learned during the initial phase of this project in annotating adverse events following influenza vaccination and related to Guillain-Barré syndrome (GBS). We emphasize on identifying the limitations of VAERS and MedDRA.
RESULTS: We collected 282 VAERS reports documented between 1990 and 2016 and shortlisted those with at least 1,100 characters in the report. We used a subset of 50 reports for the preliminary investigation and annotated all adverse events following influenza vaccination by mapping to representative MedDRA terms. Associated time expressions were annotated when available. We used 16 System Organ Class (SOC) level MedDRA terms to map GBS related adverse events and expanded some SOC terms to Lowest Level Terms (LLT) for granular representation. We annotated three broad categories of events such as problems, clinical investigations, and treatments/procedures. The inter-annotator agreement of events achieved was 86%. Incomplete reports, typographical errors, lack of clarity and coherence, repeated texts, unavailability of associated temporal information, difficulty to interpret due to incorrect grammar, use of generalized terms to describe adverse events / symptoms, uncommon abbreviations, difficulty annotating multiple events with a conjunction / common phrase, irrelevant historical events and coexisting events were some of the challenges encountered. Some of the limitations we noted are in agreement with previous reports.
CONCLUSIONS: We reported the challenges encountered and lessons learned during annotation of adverse events in VAERS reports following influenza vaccination and related to GBS. Though the challenges may be due to the inevitable limitations of public reporting systems and widely reported limitations of MedDRA, we emphasize the need to understand these limitations and extraction of other supportive information for a better understanding of adverse events following vaccination.
OBJECTIVES: Salvage transjugular intrahepatic portosystemic shunt (TIPS) is indicated in patients with active endoscopically uncontrollable variceal bleeding. TIPS alone is not effective in the management of gastric varices, and balloon occluded transvenous obliteration (BRTO) requires favourable variceal anatomy. Concomitant placement of a TIPS stent with antegrade variceal embolization leads to control of gastric variceal bleeding with no significant increase in portal pressure.
METHODS: A single-centre retrospective observational study in which patients with active uncontrollable gastric variceal bleeding were included. Technical success of the procedure, 5-day rebleeding, 6-week, and 6-month survival, as well as other additional outcomes, were evaluated.
RESULTS: A total of 18 patients were included in the study. Technical success was 100% and significant non-target embolization was seen in 0% of patients. The 6-week and 6-month survival rates were 66.67%, with an overall survival of 108.786 days (censored at 180 days). The 5-day rebleed rate was 11.1%. A significant difference in Child-Turcotte-Pugh score (P = .03), model for end-stage liver disease-sodium (MELD-Na) score (P = .022), requirement of intubation (P = .038), haemoglobin (Hb) levels (P = .042), haematocrit value (P = .018), packed red blood cell infusion required prior to and after the procedure (P = .045, .044), and presence of refractory shock (P = .013) was observed between the survival and the mortality groups. Post-variceal bleeding Hb levels, mean arterial pressure, and MELD-Na scores were significant predictors of mortality.
CONCLUSION: TIPS in adjunct to antegrade transvenous embolization is a safe and effective modality for the management of active uncontrolled gastric variceal bleeding in patients with variceal anatomy unfavourable for performing retrograde obliteration.
ADVANCES IN KNOWLEDGE: (1) TIPS alone may not be effective in the management of gastric varices. BRTO requires favourable variceal anatomy and may lead to catastrophic oesophageal variceal haemorrhage. Concomitant placement of a TIPS stent with antegrade variceal embolization leads to control of gastric variceal bleeding with no significant increase in portal pressure. (2) TIPS, in conjunction with antegrade transvenous embolization, requires proper knowledge of variceal anatomy and the embolizing agent. Post-variceal bleeding Hb levels, mean arterial pressure, and MELD-Na scores were significant predictors of mortality.
Composition (C1), for topical application, preferably on skin, mucous membrane and scalp, comprises at least three trace elements e.g. cobalt, zinc, chromium, iron, manganese, copper, molybdenum, selenium and/or vanadium. An independent claim is also included for a wound levy comprising (C1). ACTIVITY : Vulnerary; Hemostatic; Gastrointestinal-Gen. The ability of the composition to treat wound was tested in female patient of 16 years. The result showed that the wound was cleared within 3-4 days without any scars on the skin, after the applying the composition. MECHANISM OF ACTION : None given.
The invention discloses a serum 7 type haemophilus parasuis low virulent strain and application of the serum 7 type haemophilus parasuis low virulent strain. The serum 7 type haemophilus parasuis low virulent strain was preserved in China Center for Type Culture Collection on October 13th, 2016, and the preservation number is CCTCC No: M2016560. The virulence of the low virulent strain is greatly weakened, and the low virulent strain is suitable for being used for preparing the medicine for treating haemophilus parasuis. According to application of the serum 7 type haemophilus parasuis low virulent strain, the serum 7 type haemophilus parasuis low virulent strain is utilized for preparing the medicine for treating haemophilus parasuis. The medicine is a vaccine. A preparation method of the vaccine comprises the first step of preparation of a primary seed solution, the second step of preparation of a secondary seed solution, the third step of original bacteria liquid and the fourth step of preparation of the vaccine.
This is a study that will be conducted at a single site in Argentina to characterize the Pharmacokinetics (PK) profile, safety and tolerability of anti-Shiga toxin hyperimmune equine immunoglobulin F(ab')2 fragment (INM004) in 14 healthy subjects. This is a dose escalation study. Subjects will receive a single dose of an infusion of the biological product or placebo in Stage I where 2 cohorts will be assessed with 2 different doses of INM004. Subjects will receive a repeated dose (3 doses total, every 24 hs) of an infusion of the biological product or placebo in Stage II. The total duration of study participation is 4 weeks for each subject. Subjects will complete a follow-up visit at Day 30 after the dosing. Study duration is expected to last 6 months. The investigational product intent to use is for the prevention of the development of Hemolytic Uremic Syndrome (HUS) associated to Shigatoxin producing Escherichia coli (STEC).
FIELD: medical biotechnology. SUBSTANCE: the innovation deals with the method to test compounds able to induce STF-I transcription. For this purpose the cells of pancreatic insulae which express STF-I/lac Z hybrid gene are isolated, then the impact of different compounds upon STF-I expression is estimated by adding the suggested compound to STF-I/lac Z-expressing cells. Then, due to calorimetric assay a qualitative estimation of lac Z-activity is conducted both in control and treated cells. Due to this method it could be screened the great number of compounds and STF-I- inducing ones could, also, be easily identified. Another aspect of innovation deals with the method to use STF-I promoter to trace insulin-producing cells of pancreatic insulae in vivo. This method uses protein with fluorescence in a green spectrum area as an indicator. Introduction of transgene named "STF-I-protein with green fluorescence" enables to isolate, quickly and efficiently, insulin-producing cells out of pancreas. EFFECT: broadened assortment of preparations to regulate neuroendocrine system. 9 cl, 13 ex
This is an open label pilot trial in which 25 people with ALS will take clenbuterol orally at 40-80 micrograms twice daily for 24 weeks. In person visits will occur at weeks 0, 4, 12 and 24. Telephone visits will occur at weeks 1, 6, 16 and 20. During these visits several safety and efficacy outcome measures will be performed for research purposes including safety labs, thyroid functions, pregnancy testing, ALSFRS-R, FVC (forced vital capacity), and muscle strength testing (myometry). The critical test of treatment efficacy will be the comparison of the ALSFRS-R slope during treatment to the estimated pre-treatment slope. All participants will continue to have standard follow up care for their ALS at Duke (for patients followed here) or their local ALS clinic
Deferred access participants will be given usual care and gain access to the digital app at 6 months. Usual care consists of access to published resources and community support organizations, if available. The list of resources will include contact information for a suicide prevention hotline.